Vertex Pharmaceuticals (NASDAQ:VRTX) Director Sangeeta Bhatia Sells 318 Shares

Key Points

• Director Sangeeta Bhatia sold 318 shares on May 4 under a pre‑arranged Rule 10b5‑1 plan at an average price of $423.73, reducing her stake by 6.07%; the trade was disclosed in an SEC filing.
• Vertex beat Q1 expectations, reporting $4.47 EPS versus $4.24 expected and $2.99B revenue (up 8.3% YoY), with management reiterating FY2026 revenue guidance around $13.0–13.1B and citing contributions from new non‑CF products.
• Shares trade near $424—below the 50‑ and 200‑day moving averages (~$454 and $449)—and the consensus is a Moderate Buy with a $554.83 target, though recent insider selling and analyst target cuts may weigh on near‑term sentiment.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) Director Sangeeta Bhatia sold 318 shares of the business's stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $423.73, for a total value of $134,746.14. Following the completion of the sale, the director owned 4,924 shares of the company's stock, valued at approximately $2,086,446.52. This trade represents a 6.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Price Performance

VRTX traded down $5.49 on Tuesday, hitting $424.36. The company had a trading volume of 1,905,665 shares, compared to its average volume of 1,400,388. The company's fifty day moving average price is $453.82 and its 200 day moving average price is $449.48. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $507.92. The stock has a market cap of $107.94 billion, a price-to-earnings ratio of 27.68, a price-to-earnings-growth ratio of 1.84 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The firm had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same period in the previous year, the company earned $4.06 EPS. The company's revenue for the quarter was up 8.3% on a year-over-year basis. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore boosted their target price on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an "outperform" rating in a report on Friday, January 23rd. Royal Bank Of Canada lifted their price target on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the stock an "outperform" rating in a research report on Tuesday. Weiss Ratings downgraded Vertex Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, April 14th. HC Wainwright lifted their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a "buy" rating in a research report on Tuesday, March 10th. Finally, Sanford C. Bernstein dropped their price target on Vertex Pharmaceuticals from $577.00 to $572.00 and set an "outperform" rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $554.83.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 financials showed underlying strength — non‑GAAP EPS beat consensus and product revenue grew ~8% year‑over‑year, driven by cystic fibrosis and new products; management reiterated FY2026 revenue guidance around $13.0–13.1B. Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Positive Sentiment: Management highlighted pipeline progress and contribution from new disease‑area products (CASGEVY, KASJEVY/GERNAVICS), which management says accounted for a meaningful share of recent product growth — a potential multi‑year revenue driver beyond CF. VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
• Neutral Sentiment: The full earnings call transcript, slide deck and summaries are available for investors to review management’s details on commercial execution and R&D timelines (useful for modeling but not new info). Vertex (VRTX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Concise call summaries (Moby, TipRanks) reiterate execution themes and R&D updates; these help refine timing assumptions but do not alter guidance. Vertex Q1 2026 Earnings Call Summary
• Negative Sentiment: Several analysts trimmed price targets and updated forecasts after the report, citing mixed top‑line/EPS read and cautious near‑term expectations — analyst downgrades/target cuts are pressuring sentiment. These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
• Negative Sentiment: Some data providers reported revenue/EPS slightly below certain consensus figures and highlighted extensive insider selling and large institutional rebalances — factors that can amplify near‑term downside even if fundamentals remain intact. Vertex (VRTX) Stock Falls on Q1 2026 Earnings

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Earned Wealth Advisors LLC increased its position in Vertex Pharmaceuticals by 3.3% in the 4th quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company's stock worth $295,000 after buying an additional 21 shares during the period. Confluence Wealth Services Inc. increased its position in shares of Vertex Pharmaceuticals by 4.0% during the fourth quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company's stock valued at $247,000 after purchasing an additional 21 shares during the period. Williams Jones Wealth Management LLC. increased its position in shares of Vertex Pharmaceuticals by 1.9% during the fourth quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company's stock valued at $524,000 after purchasing an additional 21 shares during the period. Childress Capital Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 3.1% during the fourth quarter. Childress Capital Advisors LLC now owns 730 shares of the pharmaceutical company's stock valued at $331,000 after purchasing an additional 22 shares during the period. Finally, Central Pacific Bank Trust Division increased its position in shares of Vertex Pharmaceuticals by 0.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 5,026 shares of the pharmaceutical company's stock valued at $2,279,000 after purchasing an additional 24 shares during the period. 90.96% of the stock is owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.